OBJECTIVES: The present study presents estimates of the number of people who would become newly eligible for antiretroviral therapy if all countries adopted the 2013 WHO treatment guidelines. It also shows the cost and impact that would result if coverage expanded to 80% of those eligible. METHODS: The AIDS Impact Model (AIM) and the Goals model within the Spectrum modelling system were used for these estimates. Projections of costs and AIDS deaths are based on estimates for 116 low-income and middle-income countries. Projections of impact on HIV incidence are based on simulation modelling for 24 high burden countries, with the results scaled up to represent all low-income and middle-income countries. RESULTS: If the 2013 guidelines were adopted universally, the number eligible for treatment would rise to 28.6 million in 2013. Achieving 80% coverage would mean 28 million on antiretroviral therapy by 2025, and would avert 2.9 million deaths and 3.9 million new infections from 2013 to 2025 compared with the 2010 guidelines. CONCLUSION: The 2013 guidelines significantly expand the number eligible for treatment. Reaching those newly eligible will require additional resources, but is likely to produce significant benefits.
OBJECTIVES: The present study presents estimates of the number of people who would become newly eligible for antiretroviral therapy if all countries adopted the 2013 WHO treatment guidelines. It also shows the cost and impact that would result if coverage expanded to 80% of those eligible. METHODS: The AIDS Impact Model (AIM) and the Goals model within the Spectrum modelling system were used for these estimates. Projections of costs and AIDS deaths are based on estimates for 116 low-income and middle-income countries. Projections of impact on HIV incidence are based on simulation modelling for 24 high burden countries, with the results scaled up to represent all low-income and middle-income countries. RESULTS: If the 2013 guidelines were adopted universally, the number eligible for treatment would rise to 28.6 million in 2013. Achieving 80% coverage would mean 28 million on antiretroviral therapy by 2025, and would avert 2.9 million deaths and 3.9 million new infections from 2013 to 2025 compared with the 2010 guidelines. CONCLUSION: The 2013 guidelines significantly expand the number eligible for treatment. Reaching those newly eligible will require additional resources, but is likely to produce significant benefits.
Authors: Sara Lodi; Andrew Phillips; Roger Logan; Ashley Olson; Dominique Costagliola; Sophie Abgrall; Ard van Sighem; Peter Reiss; José M Miró; Elena Ferrer; Amy Justice; Neel Gandhi; Heiner C Bucher; Hansjakob Furrer; Santiago Moreno; Susana Monge; Giota Touloumi; Nikos Pantazis; Jonathan Sterne; Jessica G Young; Laurence Meyer; Rémonie Seng; Francois Dabis; Marie-Anne Vandehende; Santiago Pérez-Hoyos; Inma Jarrín; Sophie Jose; Caroline Sabin; Miguel A Hernán Journal: Lancet HIV Date: 2015-07-07 Impact factor: 12.767
Authors: Jonathan Colasanti; Darius McDaniel; Brent Johnson; Carlos Del Rio; Henry Sunpath; Vincent C Marconi Journal: AIDS Res Hum Retroviruses Date: 2015-12-09 Impact factor: 2.205
Authors: Timothy B Hallett; Basia Zaba; John Stover; Tim Brown; Emma Slaymaker; Simon Gregson; David P Wilson; Kelsey K Case Journal: AIDS Date: 2014-11 Impact factor: 4.177
Authors: Ellen McRobie; Alison Wringe; Jessica Nakiyingi-Miiro; Francis Kiweewa; Tom Lutalo; Gertrude Nakigozi; Jim Todd; Jeffrey William Eaton; Basia Zaba; Kathryn Church Journal: Implement Sci Date: 2017-04-05 Impact factor: 7.327
Authors: Matthew P Fox; Jacob Bor; Alana T Brennan; William B MacLeod; Mhairi Maskew; Wendy S Stevens; Sergio Carmona Journal: PLoS Med Date: 2018-06-11 Impact factor: 11.613
Authors: Menard Laurent Chihana; Helena Huerga; Gilles Van Cutsem; Tom Ellman; Stephen Wanjala; Charles Masiku; Elisabeth Szumilin; Jean Francois Etard; Mary-Ann Davies; David Maman Journal: PLoS One Date: 2018-11-26 Impact factor: 3.240
Authors: Vivek Jain; Wei Chang; Dathan M Byonanebye; Asiphas Owaraganise; Ellon Twinomuhwezi; Gideon Amanyire; Douglas Black; Elliot Marseille; Moses R Kamya; Diane V Havlir; James G Kahn Journal: PLoS One Date: 2015-12-03 Impact factor: 3.240
Authors: Evelinn Mikkelsen; Jan A C Hontelez; Justice Nonvignon; Sam Amon; Felix A Asante; Moses K Aikins; Julie van de Haterd; Rob Baltussen Journal: AIDS Date: 2017-10-23 Impact factor: 4.177